{"entity":{"id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","aka":["STELLAR-311"],"tldr":"A phase 2/3 trial testing Zanzalintinib in neuroendocrine tumours, now recruiting.","summary":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours is a phase 2/3 interventional study registered as NCT06943755, led by Exelixis, and recruiting on the registry. Official title: A Phase 2/3, Multicenter, Randomised Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumours. Planned enrolment is 440 participants (estimated). The study started in 2025-07-21 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06943755","url":"https://clinicaltrials.gov/study/NCT06943755"}],"tags":["ctgov-ingest"],"related":[],"cancers":["neuroendocrine","small-intestinal-net","pancreatic-net","lung-net"],"sections":[],"technologies":[],"targets":[],"drugs":["zanzalintinib"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06943755","phase":"2/3","setting":"A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors","sponsor":"Exelixis","started":"2025-07-21","startedType":"actual","enrolled":440,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06943755/","neighbours":{"cancer":[{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/"}],"drug":[{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}]}}